AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Recruiting
1
100.0%
No approval data available
- Generate Biomedicines, backed by Flagship Pioneering, is seeking to raise up to $425 million in its U.S. IPO with a target valuation of $2.17 billion. - The AI-powered drug discovery company uses artificial intelligence to replace traditional trial-and-error methods and create novel protein-based therapeutics focused on immunology and oncology. - The company's lead candidate GB-0895 for severe asthma treatment is currently in late-stage trials, with full enrollment expected by the first half of 2028. - The IPO comes amid a resurgent biotech market in 2026, though investors remain cautious about AI drug discovery platforms as no fully AI-discovered drug has achieved FDA approval yet.
- Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in separate IPOs on Thursday, with both companies beginning Nasdaq trading on Friday. - The offerings represent the third and fourth biotech IPOs this week, marking the busiest seven-day stretch for new biotech stock offerings in about a year. - Agomab's lead candidate ontunisertib targets fibrostenosing Crohn's disease and is currently in Phase 2 trials, while SpyGlass's bimatoprost drug-device system for glaucoma entered Phase 3 studies in July 2025. - The successful IPOs reflect growing investor confidence in biotech, with several 2025 debuts seeing share values more than double since their offerings.
- Agomab Therapeutics priced its initial public offering at $16.00 per American Depositary Share, raising $200 million in gross proceeds to fund development of novel therapies for chronic fibrotic diseases. - The clinical-stage biopharmaceutical company focuses on developing disease-modifying treatments for immunology and inflammatory diseases with high unmet medical need. - Trading on the Nasdaq Global Select Market under ticker "AGMB" began February 6, 2026, with the offering expected to close February 9, 2026. - The company's mission centers on developing therapeutics that aim to resolve fibrosis and restore organ function for patients with these challenging disorders.
- Agomab's STENOVA Phase 2a trial successfully achieved its primary safety endpoint in 103 patients with fibrostenosing Crohn's disease after 12 weeks of treatment with ontunisertib. - The investigational oral ALK5 inhibitor demonstrated a gut-restricted pharmacokinetic profile with minimal systemic exposure and no treatment-related cardiac toxicity. - Positive efficacy signals were observed across multiple exploratory endpoints including SES-CD scores and MRE parameters, supporting the drug's dual anti-inflammatory and anti-fibrotic potential. - The company plans to discuss results with regulatory authorities and prepare for Phase 2b development in this indication with no approved pharmacological therapies.
- Over 25 pharmaceutical companies are actively developing 30+ TGF-β inhibitors to address significant unmet needs in oncology and fibrosis where existing therapies show limited effectiveness. - Key pipeline advances include Keros Therapeutics initiating Phase III trials for elritercept in myelodysplastic syndromes and EpicentRx receiving FDA Fast Track designation for AdAPT-001 in soft tissue sarcoma. - Recent clinical milestones demonstrate promising efficacy across multiple indications, with companies like Isarna Therapeutics reporting positive Phase II results for retinal fibrosis treatment ISTH0036.
• Agomab Therapeutics announced positive interim results from the STENOVA Phase 2a trial, with AGMB-129 meeting all primary and secondary endpoints in fibrostenosing Crohn's disease patients after 12 weeks of treatment. • AGMB-129, an oral GI-restricted ALK5 inhibitor targeting the TGF-β pathway, demonstrated favorable safety and tolerability with high local exposure in the ileum but minimal systemic exposure. • The company has initiated an open-label extension study allowing participants to receive treatment for up to 48 additional weeks, addressing a significant unmet need in a condition affecting nearly 50% of Crohn's disease patients.
• Agomab Therapeutics has raised $89 million in Series D funding to support clinical trials for its fibrotic disease treatments, including AGMB-129. • AGMB-129, an oral small molecule inhibitor of ALK5 (TGFβ1R), is currently in a Phase IIa trial (STENOVA) for fibrostenosing Crohn’s disease, with interim results expected in early 2025. • The funding will also support the development of AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF), and AGMB-101, a liver cirrhosis candidate. • Sanofi and Invus have joined as new investors, highlighting the growing interest and investment in immunology and fibrotic disease treatments.
